Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity

S. Corradini, M. Maksimos, F. Azab, S. Arsalani, E. Nwarunma, G. Watt, R. Soutar, M. Powell, R. Henderson, J. Travers, Z. Chen, S. Wang, A. K. Azab, M. T. S. Williams · 2026

Read Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity by S. Corradini, M. Maksimos, F. Azab, S. Arsalani, E. Nwarunma, G. Watt, R. Soutar, M. Powell, R. Henderson, J. Travers, Z. Chen, S. Wang, A. K. Azab, M. T. S. Williams (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13421325.txt.

Description

S. Corradini and thirteen colleagues describe, in a 2026 paper, a drug candidate called CBPD-409 that destroys two proteins multiple myeloma cells depend on. CBP and p300 switch on growth programmes driven by the gene MYC and keep the malignant plasma cells alive; existing blockers only mute their enzyme activity, leaving their structural roles intact.

CBPD-409 instead uses a PROTAC design — a molecule that tags a target protein for the cell's disposal machinery — to remove both proteins entirely. Earlier blockers showed early clinical promise but incomplete effect, which the authors attribute to those leftover scaffolding functions. In their experiments, full degradation produced strong anti-myeloma activity, supporting complete protein removal as the stronger strategy.

Catalog record

CREATORS. Corradini, M. Maksimos, F. Azab, S. Arsalani, E. Nwarunma, G. Watt, R. Soutar, M. Powell, R. Henderson, J. Travers, Z. Chen, S. Wang, A. K. Azab, M. T. S. Williams
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE20118
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13421325

Browse the full library · About the Tower of Babel